⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 17, 2015BMC CancerOpen Access

Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer

Soo Youn Bae Sangmin Kim Jun Ho Lee Hyun-chul Lee Se Kyung Lee Won Ho Kil Seok Won Kim Jeong Eon Lee Seok Jin Nam

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

We have identified clinically and biologically distinct features of single HR+ tumors (ER-PR+ and ER + PR-) through comparison with both ER + PR+ and ER-PR- tumors. These differences were only significant in HER2- tumors, not in HER2+ tumors. Single HR+ tumors without HER2 overexpression (ER + PR-HER2- or ER-PR + HER2-) were associated with poorer survival than ER + PR + HER2- tumors, and had comparable poor survival to ER-PR-HER2- tumors (triple-negative breast cancer).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bae et al. (2015) studied this question.

synapsesocial.com/papers/69d8125266a29169b4bee226 https://doi.org/10.1186/s12885-015-1121-4

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Combination of immune checkpoint inhibitors and anti-EGFR agents in recurrent or metastatic head and neck squamous cell carcinoma: a single-center real-world cohort studyBMC Cancer · 2026
2Systemic immune-inflammation and inflammation response indices as potential adjunctive biomarkers for invasive cervical disease and cytology underestimation in patients undergoing cervical conization: a multicenter studyBMC Cancer · 2026
3Prevention of camrelizumab-induced RCCEP with thalidomide in advanced NSCLC treated with camrelizumab Plus chemotherapy as first-line treatment: a multicenter, double-blind, randomized phase II trialBMC Cancer · 2026
4Association of HER2 status with chemotherapy burden in breast cancer: a retrospective cohort studyBMC Cancer · 2026
5Androgen receptor expression, the AR/ER ratio, and progression-free survival in hormone receptor-positive/HER2-negative metastatic breast cancer treated with CDK4/6 inhibitorsBMC Cancer · 2026

Low baseline breast TLG and axillary MTV independently predict pathological complete response in HR-positive/HER2-negative breast cancerBMC Cancer · 2026
Early detection of symptoms using electronic patient-reported outcomes and a Fitbit to optimise care in metastatic breast cancer: study protocol of the SYMPHA trialBMC Cancer · 2026
Comprehensive genomic profiling to predict origin and direct site-specific personalized therapy for cancer of unknown primary in the molecular eraBMC Cancer · 2026
Platinum sensitivity and overall survival stratification in epithelial tubo-ovarian carcinoma: a comparative evaluation of large language models and gynaecological oncologistsBMC Cancer · 2026
Association between peripheral CX3CR1⁺ CD8⁺ T cell dynamics and pathological response to pembrolizumab-containing neoadjuvant chemotherapy in triple-negative breast cancerBMC Cancer · 2026

More from BMC Cancer

More from Sungkyunkwan University

More from Samsung Medical Center